Adjudicated KR KRX

Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation

Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.

CASE PROFILE & BENCHMARKS
  • Target Issuer: Samsung BioLogics Co., Ltd. (KR).
  • Fraud Period: January 1, 2018 to December 31, 2020.
  • Reported Overstatement: $3.8B.
  • Total Fines & Penalties: $7.0M.
  • Maximum Incarceration: No prison sentence.
  • Independent Auditor: Samjong KPMG.
  • Primary Schemes: acquisition accounting abuse.
  • Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $3.8B USD reported
TOTAL PENALTIES $7.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2020 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR Financial Supervisory Service (South Korea) KR

FORENSIC ACCOUNTING AUTOPSY & MECHANICS

HOW IT WAS DONE
Forensic Aspect Regulatory Record & Ledger Mechanics
Accounting Mechanics In settled proceedings with admissions, the regulator found that The company manipulated its accounting records by executing schemes under acquisition-accounting-abuse. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.
Evidentiary Finding Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.
Mechanism Definition Manipulating purchase price allocation in mergers to write down acquired assets and create artificial liability reserves that can later be reversed into earnings.
Affected Accounts Goodwill (Asset) • Acquired Tangible Assets & Receivables (Asset) • Assumed Liabilities & Restructuring Reserves
Issuer Corporate Context South Korean contract drug maker that changed the accounting treatment of an affiliate, inflating net profit by 4.5 trillion won prior to IPO.
Independent Auditor Samjong KPMG : South Korean member firm of KPMG involved in valuation of Samsung BioLogics affiliates.
Primary Discovery Method Regulatory Enforcement & Forensic Audit

ILLUSTRATIVE GENERAL LEDGER MECHANICS (ACQUISITION ACCOUNTING ABUSE AND CUSHION CREATION)

IMPROPER VS. GAAP/IFRS TREATMENT
Improper Booked Entry Proper GAAP / IFRS Treatment Accounting Distortion & Mechanism
DR: Goodwill (inflated): $150,000,000
CR: Excess Pre-Acquisition Liabilities Accrued: $100,000,000
DR: Under ASC 805, acquired assets and liabilities must be recognized at true fair value on acquisition date
CR: No arbitrary cushion reserves that distort post-merger profitability
Undervaluing acquired inventory and writing down acquired equipment to minimums, then selling the inventory at high margins in subsequent quarters to show 'synergies.'

FINANCIAL STATEMENT & RATIO DISTORTIONS

QUANTITATIVE SCREENING SIGNALS
Financial Metric / Ratio Distortion Direction Forensic Explanation
Goodwill to Total Assets Increases rapidly Purchase price overages are loaded onto non-depreciable goodwill.
Taxonomy Applicable Scheme Classifications
Correlated Schemes

CHARGED RESPONDENTS & OUTCOMES

1 NAMED PARTIES
Respondent Role Disposition & Judicial Outcome Prison Civil Penalty O&D Bar
Samsung BioLogics Co., Ltd. ISSUER Enforcement order and financial sanctions imposed. None $7.0M No

RED FLAGS OBSERVED PRIOR TO DISCOVERY

1 EARLY WARNING INDICATORS
Red Flag Indicator Period Observed Observed Forensic Anomaly Diagnostic View
CASH FLOW TO NET INCOME DIVERGENCE 2018 Operating cash flow severely diverged from reported earnings Inspect Metric →

ENFORCEMENT ACTIONS & PRIMARY DOCKETS

PRIMARY SOURCE CITATIONS
Filing Date Type & Docket ID Enforcement Order & Regulatory Findings Disposition Primary Record
September 20, 2020
foreign regulator
ENF-2018-samsung-biologics
Enforcement Action: Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation
Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.
Securities & Corporate Law Compliance
admitted Docket Record ↗

TIMELINE OF EVENTS

2 CHRONOLOGICAL MILESTONES
Date Event Category Chronological Forensic Milestone
June 1, 2018 MISSTATEMENT Material accounting irregularities commenced.
September 20, 2020 ENFORCEMENT Regulators commenced formal proceedings.